Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned new fundraising through debt or equity. The company has utilized its entire IPO proceeds of INR165 crores effectively as of FY23. It maintains a healthy liquidity position of INR138 crores as of March 31, 2023. The company remains committed to disciplined operating cash flow and liquidity management. No specific comments on raising additional funds via debt or equity were made during the Q&A or management discussion. The company is capable of funding capacity expansion and growth through internal accruals and existing liquidity.

Any current/future capex/capital investment/strategic investment?

Current year capex is planned around INR 20-25 crores initially, with additional space and phased expansion planned for another INR 10-15 crores, totaling approximately INR 40 crores over time. The INR 40 crores investment is intended to meet capacity needs for the next five years, not just short-term expansion. Regular annual capex of INR 10-15 crores is expected to manage smaller growth or maintenance needs, including a 10-15% capacity increase via debottlenecking. Injectable facility capex has increased from earlier estimates of ~INR 50 crores to ~INR 70 crores due to added lyophilize

Future growth expectations in sales/revenue/volumes?

Company is optimistic about future growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports. CDMO vertical showed 14%-15% YoY growth; management confident of sustaining growth with new customers, products, and capacity expansions. Trade Generics expected to tap into underserved markets in India's hinterlands with potential for significant growth. Exports growth is expected but with a gestation period of about 1.5 years; revenues likely to increase from year three onward. Capacity utilization currently at ~50%; peak utilization for existing CDMO facility is 60-65%, s

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is optimistic about future growth across all verticals, targeting sustained upward annual growth despite seasonal variances. Q1 FY24 EPS grew 29% Y-o-Y to INR5.79; the company intends to continue paying dividends at around 20% of consolidated profits. EBITDA margins are expected to grow by 2-3% over the medium term (3-4 years) due to operating leverage kicking in. Operating cash flows have improved significantly in FY23, with a focus on strong cash generation alongside profitability. The company aims to double CDMO revenues in five years, leveraging increasing regulatory compliance

Current/ Expected Orderbook/ Pending Orders?

CDMO business visibility typically ranges from 1 to 3 quarters: - Multinationals provide 2 to 3 quarters of visibility. - Large Indian corporates give about 1 to 2 quarters. - Smaller customers have less visibility and operate more on lead time basis. Procurement is done back-to-back against confirmed orders to manage supply chain efficiently. Business with customers is largely repeat, with continual renewal of 5+ year contracts and no customer lost in over 20 years. Product portfolio within customers keeps changing, with new product introductions and volume fluctuations occurri

Windlas Biotech LtdQ1 FY24Pharmaceuticals & Biotechnology

Windlas Biotech Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹923.4P/E: 28.7Market Cap: ₹1.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Company is optimistic about future growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports.
CDMO vertical showed 14%-15% YoY growth; management confident of sustaining growth with new customers, products, and capacity expansions.
Trade Generics expected to tap into underserved markets in India's hinterlands with potential for significant growth.
Exports growth is expected but with a gestation period of about 1.5 years; revenues likely to increase from year three onward.
Capacity utilization currently at ~50%; peak utilization for existing CDMO facility is 60-65%, supporting up to INR600 crore revenue.
Planned capex (~INR40 crore phased over years) to meet five-year capacity needs, including injectable facility commercializing from Q4 FY24.
Operating leverage is kicking in with expected 2-3% growth in EBITDA margins over medium term.
Overall, management remains confident in achieving targeted growth sustainably.

Margin guidance

Category 2

The company is optimistic about future growth across all verticals, targeting sustained upward annual growth despite seasonal variances.
Q1 FY24 EPS grew 29% Y-o-Y to INR5.79; the company intends to continue paying dividends at around 20% of consolidated profits.
EBITDA margins are expected to grow by 2-3% over the medium term (3-4 years) due to operating leverage kicking in.
Operating cash flows have improved significantly in FY23, with a focus on strong cash generation alongside profitability.
The company aims to double CDMO revenues in five years, leveraging increasing regulatory compliance and quality standards favoring established players.
Capex of around INR40 crores planned over next years to support capacity expansion aligned with revenue growth.
New product pipeline and customer base expansion are key drivers for revenue and profit growth.
Overall, confident of consistent improvements in earnings and operating performance while maintaining strong liquidity and shareholder returns.

See what Windlas Biotech Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned new fundraising through debt or equity.
The company has utilized its entire IPO proceeds of INR165 crores effectively as of FY23.
It maintains a healthy liquidity position of INR138 crores as of March 31, 2023.
The company remains committed to disciplined operating cash flow and liquidity management.
No specific comments on raising additional funds via debt or equity were made during the Q&A or management discussion.
The company is capable of funding capacity expansion and growth through internal accruals and existing liquidity.

Order book

CDMO business visibility typically ranges from 1 to 3 quarters:
- Multinationals provide 2 to 3 quarters of visibility.
- Large Indian corporates give about 1 to 2 quarters.
- Smaller customers have less visibility and operate more on lead time basis.
Procurement is done back-to-back against confirmed orders to manage supply chain efficiently.
Business with customers is largely repeat, with continual renewal of 5+ year contracts and no customer lost in over 20 years.
Product portfolio within customers keeps changing, with new product introductions and volume fluctuations occurring regularly.
For exports, there is a gestation period of about 1.5 years from dossier filing to business start.
Overall, the company tracks orders on a near-term basis rather than a multi-year order book.

See what Windlas Biotech Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year capex is planned around INR 20-25 crores initially, with additional space and phased expansion planned for another INR 10-15 crores, totaling approximately INR 40 crores over time.
The INR 40 crores investment is intended to meet capacity needs for the next five years, not just short-term expansion.
Regular annual capex of INR 10-15 crores is expected to manage smaller growth or maintenance needs, including a 10-15% capacity increase via debottlenecking.
Injectable facility capex has increased from earlier estimates of ~INR 50 crores to ~INR 70 crores due to added lyophilized vial lines and new machinery investments for higher speed, longevity, and automation.
Injectable plant mechanical completion expected by September; commercialization expected in Q4 FY24 with revenue starting in FY25.
The company is also actively looking for acquisition/expansion opportunities nearby to meet future growth demands.
All capex and expansion plans are aligned with achieving break-even promptly and supporting sustained growth in all three business verticals (CDMO, Trade Generics, Exports).

Track Windlas Biotech Ltd — get its next earnings analysis in your feed

How does Windlas Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisWindlas Biotech Ltd

Rev 3Mar 2

See where Windlas Biotech Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Windlas Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Compare Windlas Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Windlas Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →